STAT+: As its immunology work draws attention, Sanofi also pushes forward in rare disease
Stat News • 2/2/2026
Summary
Sanofi is advancing its work in rare diseases, with an experimental drug showing improvement in neurological problems associated with a rare disease. The company plans to seek approval for this drug.
Advertisement
Lindy Score Breakdown (V4.2)
60d
Age
1
Sources
from cluster
1443
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1443/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1443/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 60 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Biogen to acquire immunology biotech Apellis for $5.6 billion
Stat News • 2 days ago
STAT+: Can a psychedelic ‘coach’ make ketamine therapy even more effective?
Stat News • 2 days ago
STAT+: Psychedelic biotechs face scrutiny over YouTube promos
Stat News • 2 days ago
STAT+: Whoop, maker of health and fitness tracking wristbands, valued at $10 billion after latest fundraising
Stat News • 2 days ago
STAT+: Baby KJ scientists hit speed bump in quest to scale custom gene editor
Stat News • 2 days ago
STAT+: ‘Takeover Tuesday’ saves biotech’s quarter
Stat News • 1 day ago
STAT+: Lilly’s obesity pill enters the oral GLP-1 game, Novo responds
Stat News • Today
STAT+: Proposed ‘preclinical obesity’ diagnosis ignites global debate among experts
Stat News • Today
STAT+: Makary marks one year at FDA with focus on achievements in speech to staff
Stat News • 1 day ago
STAT+: Large AI scribe study finds modest time savings, inconsistent use
Stat News • 1 day ago